Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baloxavir plus Oseltamivir for Influenza in SCT Recipients
NCT05170009Phase 3Terminated
- Sponsor
- Weill Cornell Medicine
- Start
- Apr 2022
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of baloxavir marboxil in influenza (2 arms), sponsored by Weill Cornell Medicine. Primary endpoints: Change of Influenza Viral RNA Loads From Baseline at the End of Treatment at Day 10 and Between-treatment-arm Difference in the Change of Influenza Viral RNA Loads From Baseline at the End of Treatment at Day 10. Started Apr 2022; status: terminated.
02
Drugs
baloxavir marboxil
03
Conditions
influenza
Beyond the preview
Go deeper on NCT05170009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05170009.